Clik here to view.
How Distributed R&D Could Spark Entrepreneurship in Biopharma
This piece originally appeared in the Timmerman Report. Remember the patent cliff and the general lack of new and innovative medicines in the industry pipeline? That was the big story of the past...
View ArticleClik here to view.
How Brexit changed the way I look at biopharma’s reputation problem
This piece originally appeared in the Timmerman Report. You may have heard something recently about Britain, the European Union (EU), some vote or other, chaos, turmoil, blah, blah, blah…You might also...
View ArticleClik here to view.
Plan B
Once again, time for something different. Speculative fiction about the election and its aftermath and some wishful thinking about what could happen next. Bill folded his newspaper and sighed. The...
View ArticleClik here to view.
Want to help biopharma’s reputation problem? Tackle poverty.
This piece originally appeared in the Timmerman Report. I make a lot of lists. It’s not the right approach for everyone, but it works for me, especially when there’s a lot going on in my life....
View ArticleClik here to view.
How Valeant, Anthem, and chirping crickets suggest Saunders’ social contract...
This piece originally appeared in the Timmerman Report. When Allergan CEO Brent Saunders announced his manifesto on drug pricing at Allergan just after Labor Day, he was met with acclaim and approval...
View ArticleClik here to view.
It’s time for biopharma to embrace public health
This piece first appeared in the Timmerman Report. Some years ago when I was working for a large biopharma, I heard a story. It seems a senior scientific executive had visited and given a seminar in...
View ArticleClik here to view.
Changing small molecule exclusivity rules as a long-term drug price policy play
This piece originally appeared in the Timmerman Report We’re entering uncharted waters in the US government. I don’t think it’s hyperbolic to say there will be new regulations, new laws that we’ve...
View ArticleClik here to view.
Why Every Biopharma Lab Should Have a 3D Printer (and a Laser Cutter Too)
This article first appeared in the Timmerman Report. If there’s something most drug development people can agree upon today it’s that the industry needs more valuable new products. Too many drugs seem...
View ArticleClik here to view.
Lessons from PCSK9, and How We Know Where to Go in Drug Discovery
This article first appeared in the Timmerman Report. What drug development lessons should we take from the PCSK9 story? That might depend on how and why we know what we know. The recent news about...
View ArticleClik here to view.
How Plants in Space Might Be a Cautionary Tale for Precision Medicine
A version of this originally appeared in the Timmerman Report. When President Obama announced the Precision Medicine Initiative (PMI) back in 2015, it was a moment not unlike when a pop star drops a...
View Article
